Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Next Previous
Trial Profile

An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mifepristone (Primary)
  • Indications Cushing syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms SEISMIC
  • Sponsors Corcept Therapeutics

    • Most Recent Events

    • 18 Mar 2019 Results investigating associations between cortisol and adrenocorticotropic hormone (ACTH) levels and the development of hypokalemia in patients with ACTH-dependent Cushing syndrome treated with mifepristone presented at the 101st Annual Meeting of the Endocrine Society.
    • 14 May 2015 According to a Corcept Therapeutics media release, data from this study was presented in the posters at the 24th annual American Association of Clinical Endocrinologists in May 2015.
    • 05 Mar 2015 According to a Corcept Therapeutics media release, data from this study were presented at the 97th annual Endocrine Society Meeting (ENDO 2015).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top